EyePoint, Inc. - 8-K Filing
EyePoint completes enrollment in pivotal Phase 3 trials for DURAVYU™ treating diabetic macular edema, with topline data expected Q4 2027 (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $EYPT
More Regulatory news
- Applied Aerospace & Defense, Inc. - 10-Q Filing
- Palomar Holdings, Inc. - 8-K Filing
- UNITED GUARDIAN INC - 10-Q Filing
- Dare Bioscience, Inc. - 8-K Filing
- NEXGEL, INC. - 8-K Filing
- TEREX CORP - 8-K Filing
- Victory Capital Holdings, Inc. - 8-K Filing
- Nano Dimension Ltd. - 8-K Filing
- M-tron Industries, Inc. - 10-Q Filing
- M-tron Industries, Inc. - 8-K Filing